Nanofaber’s mission is to overcome the challenges in current treatment of articular diseases and embrace the new paradigm of precision medicine, by means of its patented “Microsponge” drug delivery system. The ambition is to become a leading provider in the rheumatology field providing a high-performance, safe, low-cost and easy to use long-lasting injection product to deliver drugs & biologics directly into the intra-articular site. Apart from reducing the frequency of painful injections for patients, Microsponge will address the need of physicians and patients struggling with side-effects and burden on intra-articular injections. Rheumatology is an entry point into the market and, eventually, Microsponge would expand its field of applications to the entire medicine.
Initially, Microsponge will be industrialized and clinically validated for treating osteoarthrosis, aiming at a GMP-compliant manufacturing system and validated clinical protocols, enough to spear-head commercialization and licensing to the over 130 pharmaceutical and biotech companies in Europe. Microsponge will also appeal to the cosmetic market (e.g. plastic surgery and fillers), which is poised to grow at a fast pace of 8% annually.